BCRX — BioCryst Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $1.64bn
- $2.21bn
- $331.41m
- 34
- 37
- 91
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 136 | 300 | 508 | 424 | 389 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 22.1 | 8.65 | 29.4 | 50.6 | 57 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 164 | 324 | 566 | 517 | 496 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.9 | 10.9 | 15.2 | 15.4 | 20.9 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 175 | 335 | 588 | 550 | 517 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 92.3 | 106 | 104 | 106 | 150 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 137 | 354 | 695 | 845 | 972 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 38.3 | -19.3 | -107 | -295 | -456 |
Total Liabilities & Shareholders' Equity | 175 | 335 | 588 | 550 | 517 |
Total Common Shares Outstanding |